Is Egrifta (Tesamorelin) Legal in North Carolina?
HealthRX.com
Egrifta is FDA-approved and requires a prescription
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug under BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Current labels / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, both dated July 29, 2026 [2][3]
- Doses / Egrifta SV 1.4 mg; Egrifta WR 1.28 mg; the two are not substitutable [2][3]
- Compounding status / In no category of FDA's bulk-substance lists for state-licensed pharmacies or outsourcing facilities [4][5][6]
What is Egrifta's federal status?
Egrifta is tesamorelin acetate, a synthetic analog of human growth hormone-releasing factor, approved under BLA 022505 [1][2]. The original approval date is November 10, 2010 [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026, and both given once daily by subcutaneous injection [2][3].
What is it approved to treat?
Only reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label says long-term cardiovascular safety has not been established and that the drug is not indicated for weight loss management because it has a weight-neutral effect [2]. It also says there are no data showing improved adherence to antiretroviral therapy [2].
Does tesamorelin require a prescription?
Yes. Egrifta is a prescription product [1]. The Egrifta SV label gives a dose of 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily, rotating sites and avoiding scar tissue, bruises and the navel [2]. The Egrifta WR label gives a dose of 1.28 mg (0.16 mL) once daily [3]. The WR label says the two formulations are not substitutable, and that they differ in dose, number of vials, reconstitution and storage [3].
Questions worth asking
What about compounded tesamorelin?
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [7]. Tesamorelin appears in no category of FDA's list of bulk drug substances for state-licensed pharmacies and physicians (updated May 14, 2026) or of FDA's list for outsourcing facilities (updated March 21, 2025). It is also not on FDA's page of bulk substances that may present significant safety risks (content dated 04/22/2026) [4][5][6]. So FDA has made no category-based statement about compounding it. Tesamorelin is also not one of the six peptides in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [8].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Do you need a prescription for tesamorelin?
Can tesamorelin be compounded?
What is the dose of Egrifta?
What is Egrifta approved for?
References
Show all 8 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Compounding and the FDA: Questions and Answers | FDA.
- Official web page.